Abstract
The benefit of intravenous abciximab as an adjunctive to percutaneous coronary intervention has been demonstrated in large-scale randomized studies. The role of intravenous abciximab is being defined in carotid angioplasty and stent placement as the procedure is gaining popularity for the treatment of high-grade carotid stenosis in patients considered high-risk for carotid endarterectomy. This paper summarizes the pathophysiological basis and the available data for the use of abciximab as an adjunct to carotid artery stenting.
MeSH terms
-
Abciximab
-
Angioplasty, Balloon, Coronary / methods*
-
Antibodies, Monoclonal / administration & dosage*
-
Carotid Artery, Internal / surgery
-
Carotid Stenosis / drug therapy
-
Carotid Stenosis / surgery
-
Combined Modality Therapy
-
Humans
-
Immunoglobulin Fab Fragments / administration & dosage*
-
Infusions, Intravenous
-
Platelet Aggregation Inhibitors / administration & dosage*
-
Randomized Controlled Trials as Topic
-
Stents*
Substances
-
Antibodies, Monoclonal
-
Immunoglobulin Fab Fragments
-
Platelet Aggregation Inhibitors
-
Abciximab